The role of resistance in HCV treatment

Best Practice and Research: Clinical Gastroenterology

Volumn 26, Issue 4, 2012, Pages 487-503

  Vermehren, Johannes ^a   Sarrazin, Christoph ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Direct acting antivirals; Hepatitis C virus; Resistance; Sequencing

Indexed keywords

ACH 1625; AMINO ACID; BI 207127; BOCEPREVIR; FALDAPREVIR; FILIBUVIR; HOST FACTOR; LOMIBUVIR; MERICITABINE; MK 5172; RNA DIRECTED RNA POLYMERASE INHIBITOR; SERINE PROTEINASE INHIBITOR; SETROBUVIR; SIMEPREVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; CROSS RESISTANCE; DRUG TREATMENT FAILURE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MONOTHERAPY; REVIEW; VIRUS RESISTANCE;

EID: 84870413046     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2012.09.011     Document Type: Article

References (98)

1. World Health Organization Hepatitis C factsheet no. 164 2011 Accessed Online on June28, 2012 http://www.whoint/mediacentre/factsheets/fs164/en/index [html]
2. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Goncales Jr. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 13 2002 975 982
3. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 9286 2001 958 965
4. R. Bartenschlager, F.L. Cosset, and V. Lohmann Hepatitis C virus replication cycle J Hepatol 53 3 2010 583 585
5. J. Vermehren, and C. Sarrazin New HCV therapies on the horizon Clin Microbiol Infect 17 2 2011 122 134
6. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 13 2011 1207 1217
7. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 25 2011 2405 2416
8. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 13 2011; 31 1195 1206
9. K.E. Sherman, S.L. Flamm, N.H. Afdhal, D.R. Nelson, M.S. Sulkowski, and G.T. Everson Response-guided telaprevir combination treatment for hepatitis C virus infection N Engl J Med 365 11 2011 1014 1024
10. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, and S. Roberts Telaprevir for retreatment of HCV infection N Engl J Med 364 25 2011 2417 2428
11. T.L. Kieffer, C. Sarrazin, J.S. Miller, M.W. Welker, N. Forestier, and H.W. Reesink Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients Hepatology 46 3 2007 631 639
12. C. Sarrazin, T.L. Kieffer, D. Bartels, B. Hanzelka, U. Muh, and M. Welker Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir Gastroenterology 132 5 2007 1767 1777
13. S. Susser, C. Welsch, Y. Wang, M. Zettler, F.S. Domingues, and U. Karey Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients Hepatology 50 6 2009 1709 1718
14. J. Vermehren, S. Susser, C.M. Lange, N. Forestier, U. Karey, and E. Hughes Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b J Viral Hepat 19 2 2012 120 127
15. A.U. Neumann, N.P. Lam, H. Dahari, D.R. Gretch, T.E. Wiley, and T.J. Layden Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy Science 282 5386 1998 103 107
16. M. Martell, J.I. Esteban, J. Quer, J. Genesca, A. Weiner, and R. Esteban Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution J Virol 66 5 1992 3225 3229
17. L. Rong, H. Dahari, R.M. Ribeiro, and A.S. Perelson Rapid emergence of protease inhibitor resistance in hepatitis C virus Sci Transl Med 2 30 2010 30ra2
18. M.H. Powdrill, E.P. Tchesnokov, R.A. Kozak, R.S. Russell, R. Martin, and E.S. Svarovskaia Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance Proc Natl Acad Sci U S A 108 51 2011 20509 20513
19. C. Sarrazin, and S. Zeuzem Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 138 2 2010 447 462
20. V. Soriano, A.S. Perelson, and F. Zoulim Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother 62 1 2008 1 4
21. E.M. Gardner, W.J. Burman, J.F. Steiner, P.L. Anderson, and D.R. Bangsberg Antiretroviral medication adherence and the development of class-specific antiretroviral resistance AIDS 23 9 2009 1035 1046
22. S. Zeuzem, V. Soriano, T. Asselah, J.P. Bronowicki, A. Lohse, and B. Mullhaupt SVR4 and SVR12 with an interferon-free regimen of BI 201335 and BI 207127, ± ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: interim results of sound-C2 J Hepatol 56 2012 S45-S
23. F. Poordad, J.P. Bronowicki, S.C. Gordon, S. Zeuzem, I.M. Jacobson, and M.S. Sulkowski Factors that predict response of patients with HCV infection to boceprevir Gastroenterology 2012 Epub ahead of print
24. I.M. Jacobson, I. Catlett, P. Marcellin, N.H. Bzowej, A.J. Muir, and N. Adda Telaprevir substantially improved SVR rates across all IL28B genotypes in the advance trial J Hepatol 54 2011 S542 S543
25. J.M. Gottwein, T.K.H. Scheel, T.B. Jensen, L. Ghanem, and J. Bukh Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses Gastroenterology 141 3 2011 1067 1079
26. R.A. Fridell, D.K. Qiu, C.F. Wang, L. Valera, and M. Gao Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system Antimicrobial Agents Chemother 54 9 2010 3641 3650
27. M. Gao, R.E. Nettles, M. Belema, L.B. Snyder, V.N. Nguyen, and R.A. Fridell Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 7294 2010 96-U108
28. J.C. Sullivan, S. De Meyer, D.J. Bartels, I. Dierynck, E. Zhang, and J. Spanks Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials J Hepatol 54 2011 S4
29. C. Sarrazin, R. Rouzier, F. Wagner, N. Forestier, D. Larrey, and S.K. Gupta SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders Gastroenterology 132 2007 1270 1278
30. D.J. Bartels, Y. Zhou, E.Z. Zhang, M. Marcial, R.A. Byrn, and T. Pfeiffer Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3/4A protease inhibitors in treatment-naive subjects J Infect Dis 198 6 2008 800 807
31. T. Kuntzen, J. Timm, A. Berical, N. Lennon, A.M. Berlin, and S.K. Young Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients Hepatology 48 6 2008 1769 1778
32. O. Lenz, B. Fevery, L. Vijgen, J. Verbeeck, M. Peeters, and M. Beumont TMC435 in combination with peginterferon alpha-2a/ribavirin in treatment-naive patients infected with HCV genotype 1: virology analysis of the pillar study Hepatology 54 2011 985A
33. I. Vicenti, A. Rosi, F. Saladini, G. Meini, F. Pippi, and B. Rossetti Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy J Antimicrob Chemother 67 4 2012 984 987
34. R.A. Fridell, C.F. Wang, J.H. Sun, D.R. O'Boyle, P. Nower, and L. Valera Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations Hepatology 54 6 2011 1924 1935
35. S. Margeridon, S. Le Pogam, T.F. Liu, B. Hanczaruk, B.B. Simen, and N. Shulman No detection of variants bearing NS5B S282T mericitabine (MCB) resistance mutation in DAA treatment-naive HCV genotype 1 (G1)-infected patients using ultra-deep pyrosequencing (UDPS) Hepatology 54 2011 532A
36. S. Gaudieri, A. Rauch, K. Pfafferott, E. Barnes, W. Cheng, and G. McCaughan Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy Hepatology 49 4 2009 1069 1082
37. S.C.C. Sun, A. Bae, X. Qi, J. Harris, K.A. Wong, and M.D. Miller Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naive HCV patient isolates J Viral Hepat 18 12 2011 861 870
38. S. Chevaliez, C. Rodriguez, A. Soulier, A. Ahmed-Belkacem, C. Hezode, and J.M. Pawlotsky Molecular characterization of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: preexisting resistant variants and dynamics of resistant populations J Hepatol 54 2011 S30
39. S. de Meyer, I. Dierynck, A. Ghys, M. Beumont, B. Daems, and B. van Baelen Characterisation of HCV variants in non-SVR patients in the realize study suggests that telaprevir exhibits a consistent resistance profile irrespective of a lead-in J Hepatol 54 2011 S475
40. S. Susser, J. Vermehren, N. Forestier, M.W. Welker, N. Grigorian, and C. Fuller Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir J Clin Virol 52 4 2011 321 327
41. K.E. Sherman, M.S. Sulkowski, F. Zoulim, A. Alberti, L.J. Wei, and J. Sullivan Follow-up of SVR durability and viral resistance in patients with chronic hepatitis C treated with telaprevir-based regimens: interim analysis of the extend study Hepatology 54 2011 485A 486A
42. R.J. Barnard, S. Zeuzem, J.M. Vierling, M.S. Sulkowski, M.P. Manns, and J.M. Long Analysis of resistance-associated amino acid variants (RAVS) in non-SVR patients enrolled in a retrospective long-term follow-up analysis of boceprevir phase 3 clinical studies Hepatology 54 2011 440A 441A
43. O. Lenz, J. de Bruijne, L. Vijgen, T. Verbinnen, C.J. Weegink, and H. van Marck Treatment outcome and resistance analysis in HCV genotype 1 patients previously exposed to TMC435 monotherapy and re-treated with TMC435 in combination with pegIFN alpha-2a/ribavirin J Hepatol 54 2011 S482 S483
44. C. Sarrazin, H.W. Reesink, S. Zeuzem, C.J. Weegink, D.H. Luo, and J. Witek Retreatment with telaprevir/peg-IFN/RBV after a short exposure to telaprevir in phase I studies: interim results from a phase IIIb rollover trial (C219) Hepatology 54 2011 377A 378A
45. S. Chevaliez, C. Rodriguez, and J.M. Pawlotsky New virologic tools for management of chronic hepatitis B and C Gastroenterology 142 6 2012 1303 1313
46. A.D. Kwong, I. Najera, J. Bechtel, S. Bowden, J. Fitzgibbon, and P. Harrington Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG Gastroenterology 140 3 2011 755 760
47. J.M. Pawlotsky Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus Hepatology 53 5 2011 1742 1751
48. J.M. Vierling, R. Ralston, E. Lawitz, J. McCone, S.C. Gordon, and D. Pound Long-term outcomes following combination treatment with boceprevir plus PEG-Intron/ribavirin (P/R) in patients with chronic hepatitis C, genotype 1 (CHC-G1) J Hepatol 52 2010 S470 S471
49. C.H.C.V. Lin NS3/4A serine protease S.L. Tan, Hepatitis C viruses: genomes and molecular biology 1st ed. 2006 Horizon Bioscience Norfolk 163 206
50. D. Lamarre, P.C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, and P. Bonneau An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus Nature 426 6963 2003 186 189
51. C. Lin, K. Lin, Y.P. Luong, B.G. Rao, Y.Y. Wei, and D.L. Brennan In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms J Biol Chem 279 17 2004 17508 17514
52. D.J. Bartels, S. De Meyer, J. Sullivan, I. Dierynck, N. Adda, and R.S. Kauffman Summary of clinical virology findings from clinical trials of telaprevir Hepatology 54 2011 Oct 984A 985A
53. S. De Meyer, K. Thys, I. Dierynck, A. Ghys, J. Aerssens, and G. Picchio Deep sequencing screening for telaprevir-resistant viral variants in previous null responders fails to identify those patients at risk of failing telaprevir plus peginterferon/ribavirin therapy J Hepatol 56 2012 S465
54. X. Tong, R. Chase, A. Skelton, T. Chen, J. Wright-Minogue, and B.A. Malcolm Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034 Antiviral Res 70 2 2006 28 38
55. P.Y. Kwo, E.J. Lawitz, J. McCone, E.R. Schiff, J.M. Vierling, and D. Pound Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 9742 2010 705 716
56. R.A. Ogert, P. McMonagle, S. Black, S. Curry, Z.Y. Guo, and C. Lesburg Genotypic and phenotypic correlates of resistance in HCV genotype 1a and 1b infected patients treated with boceprevir plus peginterferon alpha and ribavirin Hepatology 54 2011 794A 795A
57. G. Kukolj, C. Bousquet, N. Dansereau, F. Do, L. Lagace, and M. Llinas-Brunet Characterization of resistant mutants selected in vitro by the HCV NS3/4A protease inhibitor BI 201335 J Hepatol 52 2010 S295
58. O. Lenz, T. Verbinnen, T.I. Lin, L. Vijgen, M.D. Cummings, and J. Lindberg In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435 Antimicrobial Agents Chemother 54 5 2010 1878 1887
59. C. Sarrazin, S. Lim, X.L. Qin, S. Susser, C.M. Lange, and W.Z. Bradford Kinetic analysis of viral rebound and drug-resistant viral variant dynamics in patients treated with ITMN-191 (R7227) monotherapy suggest a high barrier to viral escape Hepatology 50 4 2009 953A 954A
60. G. Kukolj, L. Legace, M. Cartier, M. Marquis, I. Triki, and M.S. Sulkowski Characterization of HCV NS3 variants that emerged during virologic breakthrough and relapse from BI 201335 phase 2 silen-C1 study Hepatology 54 2011 Oct 991A
61. V. Summa, S.W. Ludmerer, J.A. McCauley, C. Fandozzi, C. Burlein, and G. Claudio MK-5172, a selective inhibitor of hepatitis C virus NS3/4A protease with broad activity across genotypes and resistant variants Antimicrobial Agents Chemother 2012 Epub ahead of print
62. J.M. Strizki, R.J.O. Barnard, C. Cheney, C. McHale, D. Graham, and A. Himmelberger Evaluation of NS3 amino acid variants in a phase 1b study of genotype 1 (GT1) and GT3 infected patients with the HCV protease inhibitor, MK-5172 J Hepatol 56 2012 S479
63. J. Fabrycki, D. Patel, G. Yang, Y. Zhao, S. Podos, and H. Robison Characterization of HCV NS3 protease variants from patients enrolled in a 28-day phase 2a trial of ACH-1625 daily dosing plus pegIFN-alpha 2a/RBV J Hepatol 56 2012 S468
64. C.T. Ranjith-Kumar, and C. Cheng Kao Biochemical activities of the HCV NS5B RNA-dependent RNA polymerase S.L. Tan, Hepatitis C viruses: genomes and molecular biology 1st ed. 2006 Horizon Bioscience Norfolk 293 310
65. N.H. Afdhal, C. O'Brien, E. Godofsky, M. Rodriguez-Torres, S.C. Pappas, and E. Lawitz Valopicitabine (NM283), alone or with peginterferon, compared to peginterferon/ribavirin (pegIFN/RBV) retreatment in patients with HCV-1 infection and prior non-response to pegIFN/RBV: one-year results J Hepatol 46 2007 S5
66. E.J. Gane, P. Pockros, S. Zeuzem, P. Marcellin, A. Shikhman, and C. Bernaards Interferon-free treatment with a combination of mericitabine and danoprevir/R with or without ribavirin in treatment-naive HCV genotype 1-infected patients J Hepatol 56 2012 S555 S556
67. E. Lawitz, J.P. Lalezari, T. Hassanein, K.V. Kowdley, F.F. Poordad, and A.M. Sheikh Once-daily PSI-7977 plus peg/RBV in treatment-naive patients with HCV GT1: robust end of treatment response rates are sustained post-treatment Hepatology 54 2011 472A 473A
68. E.J. Gane, C.A. Stedman, R.H. Hyland, R.D. Sorensen, W.T. Symonds, and R.G. Hindes Electron: once daily PSI-7977 plus RBV in HCV GT1/2/3 J Hepatol 56 2012 S438 S439
69. M. Sulkowski, D. Gardiner, E. Lawitz, F. Hinestrosa, D. Nelson, and P. Thuluvath Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), ± ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3 J Hepatol 56 2012 S560
70. P. Pockros, D. Jensen, N. Tsai, R. Taylor, A. Ramji, and C. Cooper SVR-12 among G1/4 treatment-naive patients receiving mericitabine in combination with peg-IFN alpha-2a/RBV: interim analysis from the jump-C study J Hepatol 56 2012 Apr S477 S478
71. H. Wedemeyer, D. Jensen, R. Herring, P. Ferenci, M.M. Ma, and S. Zeuzem Efficacy and safety of mericitabine (MCB) in combination with peg-IFN alpha-2a/RBV in G1/4 treatment naive HCV patients: final analysis from the propel study J Hepatol 56 2012 S481 S482
72. F.E. Membreno, and E.J. Lawitz The HCV NS5B nucleoside and non-nucleoside inhibitors Clin Liver Dis 15 3 2011 611 626
73. I.H. Shih, I. Vliegen, B. Peng, H. Yang, C. Hebner, and J. Paeshuyse Mechanistic characterization of GS-9190 (tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase Antimicrobial Agents Chemother 55 9 2011 4196 4203
74. L. Lagace, M. Cartier, G. Laflamme, C. Lawetz, M. Marquis, and I. Triki Genotypic and phenotypic analysis of the NS5B polymerase region from viral isolates of HCV chronically infected patients treated with BI 207127 for 5-days monotherapy Hepatology 52 2010 1205A 1206A
75. H. Li, J. Tatlock, A. Linton, J. Gonzalez, T. Jewell, and L. Patel Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7- dimethyl-[1,2,4]tr iazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6- dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor J Med Chem 52 5 2009 1255 1258
76. J. Mori, J.L. Hammond, S. Srinivasan, S. Jagannatha, and E. van der Ryst Genotypic characterisation of filibuvir (PF-00868554) resistance in patients receiving four weeks co-administration of filibuvir with pegIFN/RBV (12 week analysis) J Hepatol 52 2010 S15
77. D.R. Nelson, E.J. Gane, I.M. Jacobson, A.M. Di Bisceglie, K. Alves, and M.J. Koziel VX-222/telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment-naive genotype 1 HCV patients treated for 12 weeks: zenith study, SVR12 interim analysis Hepatology 54 2011 1435A
78. E.Z. Zhang, A. Tigges, M. Jiang, J. Dorrian, J. Spanks, and A. Ardzinski Characterization of HCV variants in genotype 1 treatment-naive patients administered the combination of TVR and VX-222 in dual arms of zenith study J Hepatol 56 2012 S468 S469
79. E. Lawitz, M. Rodriguez-Torres, V.K. Rustgi, T. Hassanein, M.H. Rahimy, and C.A. Crowley Safety and antiviral activity of ANA598 in combination with pegylated interferon alpha 2a plus ribavirin in treatment-naive genotype-1 chronic HCV patients Hepatology 52 4 2010 334A 335A
80. T. Middleton, J. He, J. Beyer, I.A. Gaultier, D.E. Cohen, and T.J. Podsadecki Factors affecting HCV viral load response to the non-nucleoside polymerase inhibitors ABT-072 and ABT-333 J Hepatol 54 2011 S483 S484
81. E. Lawitz, F. Poordad, K.V. Kowdley, D. Jensen, D.E. Cohen, and S. Siggelkow A 12-week interferon-free regimen of ABT-450/R, ABT-072, and ribavirin was well tolerated and achieved sustained virologic response in 91% treatment-naive HCV IL28B-CC genotype-1-infected subjects J Hepatol 56 2012 S7
82. F. Poordad, E. Lawitz, K.V. Kowdley, G.T. Everson, B. Freilich, and D. Cohen 12-Week interferon-free regimen of ABT-450/R + ABT-333 + Ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders J Hepatol 56 2012 S549 S550
83. C.M. Hebner, B. Han, K.M. Brendza, M. Nash, M. Sulfab, and Y. Tian The HCV non-nucleoside inhibitor tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function PloS One 7 6 2012 e39163
84. J. Harris, A. Bae, S.C. Sun, E.S. Svarovskaia, M.D. Miller, and H.M. Mo Antiviral response and resistance analysis of treatment-naive HCV infected subjects receiving single and multiple doses of GS-9190 Hepatology 52 2010 722A
85. C.M. Hebner, J. Harris, D. Oldach, M.D. Miller, and H. Mo Emergence and persistence of NS5B mutations following combination treatment with tegobuvir (GS-9190) plus standard of care-long-term follow-up from the phase IIb study GS-Us-196-0103 J Hepatol 54 2011 S478 S479
86. G.R. Foster, P. Buggisch, P. Marcellin, S. Zeuzem, K. Agarwal, and M. Manns Four-week treatment with GS-9256 and tegobuvir (GS-9190), ± RBV ± PEG, results in enhanced viral suppression on follow-up PEG/RBV therapy, in genotype 1a/1b HCV patients J Hepatol 54 2011 S172
87. M. Sulkowski, M. Rodriguez-Torres, E. Lawitz, M. Shiffman, S. Pol, and R. Herring High sustained virologic response rate in treatment-naive HCV genotype 1a and 1b patients treated for 12 weeks with an interferon-free all-oral quad regimen: interim results J Hepatol 56 2012 S560
88. T.L. Tellinghuisen, J. Marcotrigiano, and C.M. Rice Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase Nature 435 7040 2005 374 379
89. S. Pol, R.H. Ghalib, V.K. Rustgi, C. Martorell, G.T. Everson, and H.A. Tatum Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial Lancet Infect Dis 2012 Epub ahead of print
90. F. McPhee, D. Hernandez, F. Yu, J. Ueland, K. Chayama, and J. Toyota A description of virologic escape in HCV genotype 1-infected patients treated with daclatasvir (BMS-790052) in combination with ribavirin and peginterferon alfa-2a or peginterferon alfa-2b J Hepatol 56 2012 S473
91. A. Lok, D. Gardiner, C. Hezode, E. Lawitz, M. Bourliere, and G. Everson Confirmation that quadruple therapy with daclatasvir (NS5A inhibitor), asunaprevir (NS3 inhibitor) and peginterferon/ribavirin results in high rate of SVR4 in HCV genotype 1 null responders J Hepatol 56 2012 S557
92. E. Lawitz, T. Marbury, A. Campbell, E. Dumas, M. Kapoor, and T. Pilot-Matias Safety and antiviral activity of ABT-267, a novel NS5A inhibitor, during 3-day monotherapy: first study in HCV genotype-1 (GT1)-infected treatment-naive subjects J Hepatol 56 2012 S469 S470
93. K.A. Wong, A. Worth, D.M. Brainard, E. Lawitz, M.D. Miller, and H. Mo Persistence of NS5A GS-5885 drug resistance mutations following 3 days of monotherapy in genotype-1 HCV patients is dependent on the HCV subtype and specific mutation J Hepatol 56 2012 S482
94. C. Hezode, N. Forestier, G. Dusheiko, P. Ferenci, S. Pol, and T. Goeser Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 18 2009 1839 1850
95. I.M. Jacobson, D.J. Bartels, L. Gritz, T.L. Kieffer, S. De Meyer, and F. Tomaka Futility rules in telaprevir combination treatment J Hepatol 56 2012 S24
96. I.M. Jacobson, P. Marcellin, S. Zeuzem, M.S. Sulkowski, R. Esteban, and F. Poordad Refinement of stopping rules during treatment of hepatitis C-genotype 1 infection with boceprevir combined with peginterferon/ribavirin Hepatology 2012 Epub ahead of print
97. E.J. Gane, S.K. Roberts, C.A. Stedman, P.W. Angus, B. Ritchie, and R. Elston Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 376 9751 2010 1467 1475
98. F. Suzuki, K. Ikeda, J. Toyota, Y. Karino, T. Ohmura, and K. Chayama Dual oral therapy with the NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1b-Infected null responders or ineligible/intolerant to peginterferon/ribavirin J Hepatol 56 2012 S7 S8